Public-domain · open source
OpenJurist
← 813 P.2d 89 - Grundberg v. Upjohn Co.

Grundberg v. Upjohn Co.’s Empirical Analysis

1991

Citation profile

46
cited by 46 later decisions
7
states following
November 2025
most recently cited

14 federal appellate · 5 district · 19 state decisions

How this case has been cited

Cited by 46 later decisions — most recently November 2025 · most notably Thom v. Bristol-Myers Squibb Co. (2003), Allen v. Minnstar, Inc. (1993)

14 federal appellate · 5 district · 19 state decisions

1801991200020102020decided

Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.

Relationships

Applies 21 U.S.C. § 301 (Animal Drug Amendments of 1968) · 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act)

Relies on United States v. Sullivan · Buckley v. American Federation of Television & Radio Artists · 44 Cal. 3d 1049 - Brown v. Superior Court · 4 Cal. 3d 699 - Mozzetti v. Superior Court · Reyes v. Wyeth Laboratories

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 46 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “[tlhere are some products which, in the present state of human knowledge, are quite incapable of being made safe for their intended and ordinary use.”
    4 later decisions quote this exact passage
  2. “that manufacturers of unavoidably dangerous products should not be liable for a claim of design defect”
    3 later decisions quote this exact passage
  3. “A drug is designed to be effectively administered to specific individuals for one or a number of indications. To determine whether a drug’s benefit outweighs its risk is inherently complex because of the manufacturer’s conscious design choices regarding the numerous chemical properties of the product and their relationship to the vast physiologic idiosynera-cies of each consumer for whom the drug is designed. Society has recognized this complexity and in response has reposed regulatory authority in the FDA. Relying on the FDA’s screening and surveillance standards enables courts to find liability under circumstances of inadequate warning, mismanufacture, improper marketing, or misinforming the FDA-avenues for which courts are better suited. Although this approach denies plaintiffs one potential theory on which to rely in a drug products liability action, the benefits to society in promoting the development, availability, and reasonable price of drugs justifies this conclusion. In light of the strong public interest in the availability and affordability of prescription medications, the extensive regulatory system of the FDA, and the avenues of recovery still available to plaintiffs by claiming inadequate warning, mismanufacture, improper marketing, or misrepresenting information to the FDA, we conclude that a broad grant of immunity from strict liability claims based on design defects should be extended to FDA-approved prescription drugs in Utah.^”
    1 later decision quote this exact passage

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.